Glenmark Pharma gets ANDA approval for generic birth control drug

Image
Capital Market
Last Updated : Jul 29 2022 | 10:04 AM IST

Glenmark Pharmaceuticals Inc., USA has received final approval by the United States Food & Drug Administration (USFDA) for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg.

The approved drug is the generic version of Taytulla Capsules, of Allergan Pharmaceuticals International.

The drug is a prescription birth control pill used for the prevention of pregnancy.

According to IQVIA sales data for the 12 month period ending May 2022, the Taytulla Capsules market achieved annual sales of approximately $85.9 million.

Glenmark's current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA.

Glenmark Pharmaceuticals is a global pharmaceutical company with a presence across specialty, generics, and OTC businesses.

The pharma company's consolidated net profit slumped 33.5% to Rs 155.59 crore on a 4.6% rise in net sales to Rs 2,961.15 crore in Q4 FY22 over Q4 FY21.

The scrip advanced 0.86% to settle at Rs 379.90 on Thursday, 28 July 2022.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 29 2022 | 8:55 AM IST

Next Story